share_log

Bristol-Myers Squibb | 4: Statement of changes in beneficial ownership of securities-Officer Elkins David V

SEC announcement ·  Mar 12 17:48
Summary by Moomoo AI
On March 10, 2024, David V Elkins, EVP and Chief Financial Officer of Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Elkins exercised options to acquire a total of 64,326 shares at no cost. Concurrently, he disposed of 37,970 shares through various means, including the payment of exercise price or tax liability, with some transactions priced at $53.79 per share. The total market value of the disposed shares amounted to $996,298.38. Following these transactions, Elkins directly held 194,968 shares of Bristol-Myers Squibb. Additionally, he indirectly held 215.72 shares through the BMS Savings and Investment Program.
On March 10, 2024, David V Elkins, EVP and Chief Financial Officer of Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Elkins exercised options to acquire a total of 64,326 shares at no cost. Concurrently, he disposed of 37,970 shares through various means, including the payment of exercise price or tax liability, with some transactions priced at $53.79 per share. The total market value of the disposed shares amounted to $996,298.38. Following these transactions, Elkins directly held 194,968 shares of Bristol-Myers Squibb. Additionally, he indirectly held 215.72 shares through the BMS Savings and Investment Program.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more